{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:58:50Z","timestamp":1790117930075,"version":"4.0.1"},"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Buprenorphine is a \u03bc-opioid receptor (MOR) partial agonist used to manage pain and addiction. QT\n                    <jats:sub>C<\/jats:sub>\n                    prolongation that crosses the 10 msec threshold of regulatory concern was observed at a supratherapeutic dose in two thorough QT studies for the transdermal buprenorphine product BUTRANS\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . Because QT\n                    <jats:sub>C<\/jats:sub>\n                    prolongation can be associated with Torsades de Pointes (TdP), a rare but potentially fatal ventricular arrhythmia, these results have led to further investigation of the electrophysiological effects of buprenorphine. Drug-induced QT\n                    <jats:sub>C<\/jats:sub>\n                    prolongation and TdP are most commonly caused by acute inhibition of hERG current (I\n                    <jats:sub>hERG<\/jats:sub>\n                    ) that contribute to the repolarizing phase of the ventricular action potentials (APs). Concomitant inhibition of inward late Na\n                    <jats:sup>+<\/jats:sup>\n                    (I\n                    <jats:sub>NaL<\/jats:sub>\n                    ) and\/or L-type Ca\n                    <jats:sup>2+<\/jats:sup>\n                    (I\n                    <jats:sub>CaL<\/jats:sub>\n                    ) current can offer some protection against proarrhythmia. Therefore, we characterized the effects of buprenorphine and its major metabolite norbuprenorphine on cardiac hERG, Ca\n                    <jats:sup>2+<\/jats:sup>\n                    , and Na\n                    <jats:sup>+<\/jats:sup>\n                    ion channels, as well as cardiac APs. For comparison, methadone, a MOR agonist associated with QT\n                    <jats:sub>C<\/jats:sub>\n                    prolongation and high TdP risk, and naltrexone and naloxone, two opioid receptor antagonists, were also studied. Whole cell recordings were performed at 37\u00b0C on cells stably expressing hERG, Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.2, and Na\n                    <jats:sub>V<\/jats:sub>\n                    1.5 proteins. Microelectrode array (MEA) recordings were made on human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The results showed that buprenorphine, norbuprenorphine, naltrexone, and naloxone had no effect on I\n                    <jats:sub>hERG<\/jats:sub>\n                    , I\n                    <jats:sub>CaL<\/jats:sub>\n                    , I\n                    <jats:sub>NaL<\/jats:sub>\n                    , and peak Na\n                    <jats:sup>+<\/jats:sup>\n                    current (I\n                    <jats:sub>NaP<\/jats:sub>\n                    ) at clinically relevant concentrations. In contrast, methadone inhibited I\n                    <jats:sub>hERG<\/jats:sub>\n                    , I\n                    <jats:sub>CaL<\/jats:sub>\n                    , and I\n                    <jats:sub>NaL<\/jats:sub>\n                    . Experiments on iPSC-CMs showed a lack of effect for buprenorphine, norbuprenorphine, naltrexone, and naloxone, and delayed repolarization for methadone at clinically relevant concentrations. The mechanism of QT\n                    <jats:sub>C<\/jats:sub>\n                    prolongation is opioid moiety-specific. This remains undefined for buprenorphine, while for methadone it involves direct hERG channel block. There is no evidence that buprenorphine use is associated with TdP. Whether this lack of TdP risk can be generalized to other drugs with QT\n                    <jats:sub>C<\/jats:sub>\n                    prolongation not mediated by acute hERG channel block warrants further study.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0241362","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T13:24:37Z","timestamp":1604669077000},"page":"e0241362","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block"],"prefix":"10.1371","volume":"15","author":[{"given":"Phu N.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Alvarez","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thiebaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8286-9679","authenticated-orcid":true,"given":"Donna A.","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-9771","authenticated-orcid":true,"given":"Dakshesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1123-3152","authenticated-orcid":true,"given":"Ksenia","family":"Blinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-4840","authenticated-orcid":true,"given":"Wendy W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"issue":"1","key":"pone.0241362.ref001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00325481.2017.1270156","article-title":"Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials","volume":"129","author":"SC Harris","year":"2017","journal-title":"Postgrad Med"},{"issue":"6","key":"pone.0241362.ref002","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/14622416.7.6.889","article-title":"Can pharmacogenetics help rescue drugs withdrawn from the market?","volume":"7","author":"RR Shah","year":"2006","journal-title":"Pharmacogenomics"},{"issue":"3","key":"pone.0241362.ref003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40264-013-0016-z","article-title":"Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated?","volume":"36","author":"N Stockbridge","year":"2013","journal-title":"Drug Saf"},{"issue":"Suppl 4","key":"pone.0241362.ref004","first-page":"iv6","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine","volume":"92","author":"L Belardinelli","year":"2006","journal-title":"Heart"},{"issue":"5","key":"pone.0241362.ref005","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0735-1097(95)00313-4","article-title":"Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome","volume":"26","author":"W Shimizu","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0241362.ref006","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/CIRCEP.113.000322","article-title":"Combined Na(+)\/Ca(2+) exchanger and L-type calcium channel block as a potential strategy to suppress arrhythmias and maintain ventricular function","volume":"6","author":"VJ Bourgonje","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"pone.0241362.ref007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/19336950.2019.1697127","article-title":"PI3Kalpha in cardioprotection: Cytoskeleton, late Na(+) current, and mechanism of arrhythmias","volume":"13","author":"P Zhabyeyev","year":"2019","journal-title":"Channels (Austin)"},{"key":"pone.0241362.ref008","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2019.05.008","article-title":"Inhibition of PI3Kinase-alpha is pro-arrhythmic and associated with enhanced late Na(+) current, contractility, and Ca(2+) release in murine hearts","volume":"132","author":"P Zhabyeyev","year":"2019","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"pone.0241362.ref009","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41598-017-01056-0","article-title":"Inhibition of late sodium current suppresses calcium-related ventricular arrhythmias by reducing the phosphorylation of CaMK-II and sodium channel expressions","volume":"7","author":"XH Wei","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0241362.ref010","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.102.038240","article-title":"Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents","volume":"303","author":"AN Katchman","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"pone.0241362.ref011","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/ALN.0b013e3182557917","article-title":"Local anesthetic-like inhibition of voltage-gated Na(+) channels by the partial mu-opioid receptor agonist buprenorphine","volume":"116","author":"A Leffler","year":"2012","journal-title":"Anesthesiology"},{"issue":"2","key":"pone.0241362.ref012","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/sj.bjp.0702774","article-title":"Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states","volume":"128","author":"BD Walker","year":"1999","journal-title":"British journal of pharmacology"},{"issue":"2","key":"pone.0241362.ref013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern","volume":"50","author":"GE Kirsch","year":"2004","journal-title":"Journal of pharmacological and toxicological methods"},{"issue":"8","key":"pone.0241362.ref014","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.hrthm.2005.04.029","article-title":"Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C","volume":"2","author":"J Guo","year":"2005","journal-title":"Heart Rhythm"},{"issue":"1","key":"pone.0241362.ref015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.vascn.2005.04.008","article-title":"Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature","volume":"52","author":"JA Yao","year":"2005","journal-title":"Journal of pharmacological and toxicological methods"},{"issue":"8","key":"pone.0241362.ref016","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.bjp.0706678","article-title":"Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin","volume":"147","author":"AJ Alexandrou","year":"2006","journal-title":"British journal of pharmacology"},{"issue":"7","key":"pone.0241362.ref017","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/jat.3074","article-title":"Assessment of temperature-induced hERG channel blockade variation by drugs","volume":"35","author":"RR Kauthale","year":"2015","journal-title":"J Appl Toxicol"},{"issue":"43","key":"pone.0241362.ref018","doi-asserted-by":"crossref","first-page":"44690","DOI":"10.1074\/jbc.M408344200","article-title":"Cardiac IKr channels minimally comprise hERG 1a and 1b subunits","volume":"279","author":"EM Jones","year":"2004","journal-title":"J Biol Chem"},{"issue":"2b","key":"pone.0241362.ref019","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1476-5381.2011.01378.x","article-title":"hERG subunit composition determines differential drug sensitivity","volume":"164","author":"N Abi-Gerges","year":"2011","journal-title":"British journal of pharmacology"},{"issue":"1","key":"pone.0241362.ref020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature","volume":"74","author":"Z Zhou","year":"1998","journal-title":"Biophys J"},{"issue":"7","key":"pone.0241362.ref021","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1161\/CIRCRESAHA.108.185249","article-title":"Physiological properties of hERG 1a\/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome","volume":"103","author":"H Sale","year":"2008","journal-title":"Circulation research"},{"key":"pone.0241362.ref022","doi-asserted-by":"crossref","first-page":"106605","DOI":"10.1016\/j.vascn.2019.106605","article-title":"Drug potency on inhibiting late Na(+) current is sensitive to gating modifier and current region where drug effects were measured","volume":"100","author":"M Wu","year":"2019","journal-title":"Journal of pharmacological and toxicological methods"},{"issue":"14","key":"pone.0241362.ref023","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"MJ Curtis","year":"2015","journal-title":"British journal of pharmacology"},{"issue":"1","key":"pone.0241362.ref024","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kfw200","article-title":"Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias","volume":"155","author":"K Blinova","year":"2017","journal-title":"Toxicol Sci"},{"issue":"13","key":"pone.0241362.ref025","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment","volume":"24","author":"K Blinova","year":"2018","journal-title":"Cell Rep"},{"issue":"4","key":"pone.0241362.ref026","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.273","article-title":"A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients","volume":"91","author":"J Florian","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"pone.0241362.ref027","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00549595","article-title":"Naloxone protein binding in adult and foetal plasma","volume":"27","author":"LA Asali","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pone.0241362.ref028","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"WS Redfern","year":"2003","journal-title":"Cardiovasc Res"},{"issue":"2","key":"pone.0241362.ref029","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"G Gintant","year":"2011","journal-title":"Pharmacol Ther"},{"issue":"1","key":"pone.0241362.ref030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related Data","volume":"159","author":"CE Pollard","year":"2017","journal-title":"Toxicol Sci"},{"issue":"7","key":"pone.0241362.ref031","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.amjcard.2004.11.055","article-title":"Impact of methadone treatment on cardiac repolarization and conduction in opioid users","volume":"95","author":"BA Martell","year":"2005","journal-title":"Am J Cardiol"},{"issue":"22","key":"pone.0241362.ref032","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","article-title":"QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial","volume":"167","author":"EF Wedam","year":"2007","journal-title":"Arch Intern Med"},{"issue":"10","key":"pone.0241362.ref033","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/bcp.13326","article-title":"QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings","volume":"83","author":"GK Isbister","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pone.0241362.ref034","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clinthera.2015.12.004","article-title":"Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From micro-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects","volume":"38","author":"B Darpo","year":"2016","journal-title":"Clin Ther"},{"key":"pone.0241362.ref035","first-page":"859","article-title":"Buprenorphine\u2014an attractive opioid with underutilized potential in treatment of chronic pain","volume":"8","author":"IK Khanna","year":"2015","journal-title":"J Pain Res"},{"issue":"3","key":"pone.0241362.ref036","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1476-5381.1989.tb12019.x","article-title":"The antiarrhythmic and cardiac electrophysiological effects of buprenorphine","volume":"97","author":"G Boachie-Ansah","year":"1989","journal-title":"British journal of pharmacology"},{"issue":"2","key":"pone.0241362.ref037","first-page":"688","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"P Huang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"pone.0241362.ref038","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40263-013-0096-4","article-title":"Targeted opioid receptor antagonists in the treatment of alcohol use disorders","volume":"27","author":"MJ Niciu","year":"2013","journal-title":"CNS Drugs"},{"issue":"2 Suppl","key":"pone.0241362.ref039","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"AM Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"pone.0241362.ref040","first-page":"III","article-title":"Naloxone has local anesthetic effects on canine cardiac purkinje fibers","volume":"72","author":"LH Frame","year":"1985","journal-title":"Circulation"},{"issue":"3","key":"pone.0241362.ref041","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0014-2999(89)90340-3","article-title":"Antiarrhythmic properties of naloxone: an electrophysiological study on sheep cardiac Purkinje fibers","volume":"162","author":"E Cerbai","year":"1989","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"pone.0241362.ref042","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1476-5381.1986.tb16245.x","article-title":"Influence of the optical isomers (+)- and (-)-naloxone on beating frequency, contractile force and action potentials of guinea-pig isolated cardiac preparations","volume":"88","author":"H Brasch","year":"1986","journal-title":"British journal of pharmacology"},{"issue":"2","key":"pone.0241362.ref043","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cvr\/27.2.296","article-title":"Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone","volume":"27","author":"KG Oldroyd","year":"1993","journal-title":"Cardiovasc Res"},{"issue":"14","key":"pone.0241362.ref044","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0024-3205(98)00383-X","article-title":"Electrophysiological mechanisms for the antiarrhythmic activities of naloxone on cardiac tissues","volume":"63","author":"CF Hung","year":"1998","journal-title":"Life Sci"},{"issue":"4","key":"pone.0241362.ref045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/mol.118.114751","article-title":"Blockade of the Human Ether A-Go-Go-Related Gene (hERG) Potassium Channel by Fentanyl","volume":"95","author":"JN Tschirhart","year":"2019","journal-title":"Molecular pharmacology"},{"issue":"3","key":"pone.0241362.ref046","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12012-010-9074-y","article-title":"Comparison of the effects of methadone and heroin on human ether-a-go-go-related gene channels","volume":"10","author":"BJ Zunkler","year":"2010","journal-title":"Cardiovasc Toxicol"},{"issue":"5","key":"pone.0241362.ref047","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"CB Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"pone.0241362.ref048","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/FJC.0b013e3181f1d21b","article-title":"Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels","volume":"56","author":"YA Kuryshev","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"pone.0241362.ref049","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bph.12465","article-title":"The opioid methadone induces a local anaesthetic-like inhibition of the cardiac Na(+) channel, Na(v)1.5","volume":"171","author":"V Schulze","year":"2014","journal-title":"British journal of pharmacology"},{"issue":"2","key":"pone.0241362.ref050","first-page":"298","article-title":"Effects of dl-methadone on the response to physiological transmitters and on several functional parameters of the isolated guinea-pig heart","volume":"282","author":"L Mantelli","year":"1986","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"1","key":"pone.0241362.ref051","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vascn.2008.10.004","article-title":"Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability","volume":"59","author":"JC Brimecombe","year":"2009","journal-title":"Journal of pharmacological and toxicological methods"},{"issue":"3","key":"pone.0241362.ref052","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.yrtph.2013.10.001","article-title":"In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis","volume":"67","author":"S Goineau","year":"2013","journal-title":"Regul Toxicol Pharmacol"},{"key":"pone.0241362.ref053","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2017.11.002","article-title":"Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment","volume":"90","author":"D Schocken","year":"2018","journal-title":"Journal of pharmacological and toxicological methods"},{"issue":"2","key":"pone.0241362.ref054","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF00512070","article-title":"Inhibition via opioid mu- and delta-receptors of vagal transmission in rabbit isolated heart","volume":"328","author":"R Weitzell","year":"1984","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"pone.0241362.ref055","first-page":"1087","article-title":"Effects of opioid agonists on sympathetic and parasympathetic transmission to the dog heart","volume":"250","author":"T Musha","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"issue":"3\u20134","key":"pone.0241362.ref056","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0014-2999(84)90565-X","article-title":"Inhibition of the cardiac response to sympathetic nerve stimulation by opioid peptides and its potentiation by morphine and methadone","volume":"102","author":"F Ledda","year":"1984","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"pone.0241362.ref057","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0306-3623(87)90017-6","article-title":"On the presence of opioid receptors in guinea-pig ventricular tissue","volume":"18","author":"L Mantelli","year":"1987","journal-title":"Gen Pharmacol"},{"issue":"6","key":"pone.0241362.ref058","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00380-013-0456-5","article-title":"The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue","volume":"29","author":"P Sobanski","year":"2014","journal-title":"Heart Vessels"},{"issue":"3","key":"pone.0241362.ref059","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/01.RES.60.3.393","article-title":"Cardiovascular effects of calcitonin gene-related peptides I and II in man","volume":"60","author":"A Franco-Cereceda","year":"1987","journal-title":"Circulation research"},{"issue":"6","key":"pone.0241362.ref060","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"SM Brown","year":"2011","journal-title":"Anesthesiology"},{"issue":"1\u20133","key":"pone.0241362.ref061","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2005.08.008","article-title":"[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists","volume":"520","author":"JA Cassel","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"pone.0241362.ref062","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bph.12796","article-title":"BU08073 a buprenorphine analogue with partial agonist activity at mu-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice","volume":"172","author":"TV Khroyan","year":"2015","journal-title":"British journal of pharmacology"},{"key":"pone.0241362.ref063","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications","volume":"178","author":"L Toll","year":"1998","journal-title":"NIDA Research Monograph"},{"issue":"3","key":"pone.0241362.ref064","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs","volume":"59","author":"DA Volpe","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"pone.0241362.ref065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bmcl.2008.10.134","article-title":"Syntheses and opioid receptor binding properties of carboxamido-substituted opioids","volume":"19","author":"MP Wentland","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"pone.0241362.ref066","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1471-4159.2008.05833.x","article-title":"Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene","volume":"108","author":"J Xu","year":"2009","journal-title":"J Neurochem"},{"issue":"1","key":"pone.0241362.ref067","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(01)01282-1","article-title":"Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors","volume":"428","author":"N Zaveri","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"3 Pt 2","key":"pone.0241362.ref068","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.15-03-02396.1995","article-title":"The human mu opioid receptor: modulation of functional desensitization by calcium\/calmodulin-dependent protein kinase and protein kinase C","volume":"15","author":"A Mestek","year":"1995","journal-title":"J Neurosci"},{"issue":"1","key":"pone.0241362.ref069","first-page":"423","article-title":"Characterization of the cloned human mu opioid receptor","volume":"272","author":"K Raynor","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"pone.0241362.ref070","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.bmcl.2008.12.093","article-title":"14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies","volume":"19","author":"G Li","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"pone.0241362.ref071","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1124\/jpet.106.118810","article-title":"Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment","volume":"321","author":"D Wang","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"pone.0241362.ref072","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1021\/jm061327z","article-title":"Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors","volume":"50","author":"X Peng","year":"2007","journal-title":"J Med Chem"},{"issue":"2","key":"pone.0241362.ref073","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-2999(89)90582-7","article-title":"Mu opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain","volume":"167","author":"M Titeler","year":"1989","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"pone.0241362.ref074","first-page":"848","article-title":"Modulation by mu-opioid agonists of guanosine-5\u2019-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells","volume":"47","author":"JR Traynor","year":"1995","journal-title":"Molecular pharmacology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T22:02:54Z","timestamp":1618264974000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241362"}},"subtitle":[],"editor":[{"given":"Daniel M.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241362","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]}}}